UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

| (Check one): ⊠ Form 10-K | ☐ Form 20-F | ☐ Form 11-K | ☐ Form 10-Q | ☐ Form 10-D | ☐ Form N-SAR | ☐ Form N-CSR |
|--|---|-------------------|---------------------|--------------------|----------------------|----------------------|
| For Period Ended: December | 31, 2018 | | | | | |
| ☐ Transition Report on | n Form 20-F n Form 11-K n Form 10-Q | | | | | |
| For the Transition Period | Ended: | | | | | |
| _ | this form shall be | e construed to in | iply that the Con | ımission has veri | • | on contained herein. |
| If the notification relates to a | portion of the fili | ng checked above | , identify the Item | (s) to which the n | otification relates: | |
| PART I — REGISTRANT | INFORMATION | ſ | | | | |
| Medicine Man Technologies, | Inc. | | | | | |
| Full Name of Registrant | | | | | | |
| Former Name if Applicable | | | | | | |
| 4880 Havana Street, Suite 20 | 1 | | | | | |
| Address of Principal Executiv | ve Office (Street a | nd Number) | | | | |
| Denver, CO 80239 | | | | | | |
| City, State and Zip Code | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file its annual report on Form 10-K for the year ended December 31, 2018 within the prescribed period. The compilation, dissemination and review of the financial information required to be presented in the Form 10-K has imposed time constraints on the Company's management that have rendered timely filing of the Form 10-K impractical without undue hardship and expense to the Company. At this time, the Company expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date, as permitted by Rule 12b-25.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Andy Williams303371-0387(Name)(Area Code)(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes \boxtimes No \square
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes \square No \boxtimes

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

MEDICINE MAN TECHNOLOGIES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 29, 2019

MEDICINE MAN TECHNOLOGIES, INC.

By: /s/ Andy Williams

Andy Williams

Interim Chief Executive Officer